Carregant...
COVID-19 and the neurological disease therapeutic pipeline
From the interruption of clinical trials by shelter-in-place orders to the challenges involved in safely collecting biofluid samples, drug development for neurological disease was hit hard by the COVID-19 pandemic this year. However, the field has responded with innovative solutions, and 2021 could...
Guardat en:
| Publicat a: | Nat Rev Neurol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7747002/ https://ncbi.nlm.nih.gov/pubmed/33340023 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41582-020-00445-w |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|